STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

A new type of CAR T-cell therapy elicits a more controlled immune response to cancer in mice, effectively killing cancer ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

New research is challenging one of medicine’s oldest assumptions: that cancer must be attacked to be cured. By treating ...

USC researchers have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively killing cancer cells, including those ...

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high ...

A revolutionary immune therapy that uses the body's own defences to fight illness has cured patients with the blood cancer ...

A Leicester teen is “really well” after being the first to receive a pioneering blood cancer treatment. Alyssa Tapley was ...

Almost two thirds of patients with T-cell acute lymphoblastic leukaemia involved in a clinical trial of the treatment are now disease-free.